NeoAg Summit 2018

3rd Annual Neoantigen Summit is organized by Hanson Wade and will be held from Nov 14 - 16, 2018 at Hyatt Regency Cambridge, Cambridge, Massachusetts, United States of America.

Course Description:
The NeoAg Summit is the leading industry-focused meeting dedicated to ensuring improved identification, utilization and immune monitoring, to ensure the successful clinical development of truly individualized neoantigen-based vaccines and immunotherapies.

The NeoAg Summit US is the leading end-to-end summit dedicated to supercharging the targeting of cell and vaccine immunotherapies to accelerate to clinic safe, effective and scalable individualized neoantigen-based therapies.

In a rapidly evolving field, the NeoAg Summit is the key platform to benchmark your therapy, exclusively network with the key thought leaders and overcome major challenges from prediction and discovery of neoantigens to clinical development and manufacturing.

Previously we focused extensively on the technologies for identifying neoantigens and the bioinformatics approaches that have been developed to enhance epitope prediction, however as we look to move the field forward the 3rd Annual NeoAg Summit the US will take a deep dive into ensuring the neoantigens selected are immunogenic and manufacturing processes are cost effective.

Hear maturing clinical updates on current programs, regulations for products and how to manufacture for individualized therapeutics. Gathering the pioneers as we continue on the journey to clinical development of neoantigen-based immunotherapies the NeoAg Summit will share key insights to guide your commercial roadmap to success.

Speakers: Richard Gaynor: Neon Therapeutics , Andrew Allen: Gritstone Oncology, Drew Pardoll: Johns Hopkins Medicine, Fred Ramsdell: Parker Institute for Cancer Immunotherapy, Laronna Colbert: CBER, FDA, Christiane Niederlaender: EMA, Dennis Christensen: Statens Serum Institute, David Pajerowski: Moderna Therapeutics, Kaïdre Bendjama: Transgene SA, Rachel Marty: University of California San Diego, Jessica Flechtner: Genocea Biosciences, Roman Yelensky: Gritstone Oncology, Eli Gilboa: University of Miami, Alex Franzusoff: PACT Pharma, Magnus Jaderberg: Targovax, Elisa Scarselli: Nouscom AG, Antonella Vitiello: PersImmune, Alex Karlsson-Parra: Immunicum AB, Dennis Underwood: Agenus, William Watt: EpiThany, Mette Husbyn: Vaccibody, Alena Gros: Tumour Immunology and Immunotherapy, Mark Findeis: Agenus, Mahesh Yadav: Genentech, Stephen Johnston: Calviri, Jeff Roix: NeoPhore, Hideho Okada: University of California, San Francisco, Marc Wolfgang: Neon Therapeutics, Erin E. Jones: Gritstone Oncology, Keith Knutson: Mayo Clinic, Rongfu Wang: Houston Methodist, Sean Boyle: Personalis, Sune Justesen: Immunitrack, Trevor Clancy: OncoImmunity

Time: 8:00 am - 5:00 pm